Radiant Biotherapeutics (“Radiant”) secures $35 million in Series A financing.
The round was co-led by Amplitude Ventures and the Bill & Melinda Gates Foundation, both of whom share Radiant's vision of providing powerful, multifunctional biologics that can advance treatments for patients suffering from debilitating and life-threatening diseases.
Several other investors, including BDC Capital, FACIT, Alexandria Venture Investments, and Toronto Innovation Acceleration Partners (TIAP), participated in the Series A round.
The funds will enable Radiant to further develop its new multivalent, multispecific antibody platform, Multabody™, and advance it into clinical trials.
A Fasken team composed of Jonathan Raizenne, Guillaume Synnott and Dalia Tullio advised Amplitude Ventures in this funding.
